Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial

被引：6
|
作者：
Baize, N. [1 ]
Monnet, I. [2 ]
Greillier, L. [3 ]
Geier, M. [4 ]
Lena, H. [5 ]
Janicot, H. [6 ]
Vergnenegre, A. [7 ]
Crequit, J. [8 ]
Lamy, R. [9 ]
Auliac, J. B. [10 ]
Le Treut, J. [11 ]
Le Caer, H. [12 ]
Gervais, R. [13 ]
Dansin, E. [14 ]
Madroszyk, A. [15 ]
Renault, P. [16 ]
Legarff, G. [17 ]
Schott, R. [18 ]
Saulnier, P. [1 ]
Chouaid, C. [2 ]
机构：
[1] CHU Angers, Angers, France
[2] Chi Creteil, Pneumol, Creteil, France
[3] Ap Marseille, Serv Oncol Multidisciplinaire & Innovat Therapeut, Marseille, France
[4] CHU Brest, Inst Cancerol & Hematol, Brest, France
[5] CHU Rennes, Serv Pneumol, Rennes, France
[6] Hop Montpied, CHU, Clermont Ferrand, France
[7] CHU Limoges, Limoges, France
[8] Ch Beauvais, Beauvais, France
[9] Ch Bretagen Sud, Lorient, France
[10] Ctr Hosp F Quesnay, Mantes La Jolie, France
[11] Ctr Hosp Pays Aix, Aix En Provence, France
[12] Ctr Hosp St Brieuc, St Brieuc, France
[13] Ctr Francois Baclesse, Caen, France
[14] Ctr Oscar Lambret, Lille, France
[15] Inst Paoli Calmette, Marseille, France
[16] Ch Pau, Pau, France
[17] Ctr Hosp St Brieux, St Brieux, France
[18] Clcc Paul Strauss, Strasbourg, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Small Cell Lun Cancer; second line; phase; 3; trial;
D O I：
10.1016/j.jtho.2019.08.490
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA15.02
引用
收藏
页码：S246 / S246
页数：1
相关论文
共 50 条
  • [11] Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer
    Reck, M
    von Pawel, J
    Macha, HN
    Kaukel, E
    Deppermann, KM
    Bonnet, R
    Ulm, K
    Hessler, S
    Gatzemeier, U
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (15) : 1118 - 1127
  • [12] Combined chemotherapy with etoposide, irinotecan plus cisplatin compared with topotecan monotherapy as the second-line treatment in sensitive relapsed small cell lung cancer: A retrospective analysis
    Wang, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [13] Topotecan effective for second-line treatment of small cell lung cancer
    不详
    IRISH MEDICAL JOURNAL, 1997, 90 (05) : 198 - 198
  • [14] A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer
    Sculier, JP
    Lafitte, JJ
    Lecomte, J
    Berghmans, T
    Thiriaux, J
    Van Cutsem, O
    Efremidis, A
    Ninane, V
    Paesmans, M
    Mommen, P
    Klastersky, J
    ANNALS OF ONCOLOGY, 2002, 13 (09) : 1454 - 1459
  • [15] Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease
    Ardizzoni, A
    Hansen, H
    Dombernowsky, P
    Gamucci, T
    Kaplan, S
    Postmus, P
    Giaccone, G
    Schaefer, B
    Wanders, J
    Verweij, J
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 2090 - 2096
  • [16] Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer
    Kosmas, C
    Tsavaris, NB
    Malamos, NA
    Vadiaka, M
    Koufos, C
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) : 119 - 126
  • [17] A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer
    Jones, Suzanne
    Thompson, Dana
    Barton, John
    Patton, Jeff
    Shipley, Dianna
    Greco, E. Anthony
    Spigel, David
    Infante, Jeff
    Burris, Howard A., III
    CLINICAL LUNG CANCER, 2008, 9 (03) : 154 - 159
  • [18] Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line trials
    Ardizzoni, Andrea
    Tiseo, Marcello
    Boni, Luca
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2211 - 2218
  • [19] Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331
    Spigel, D. R.
    Vicente, D.
    Ciuleanu, T. E.
    Gettinger, S.
    Peters, S.
    Horn, L.
    Audigier-Valette, C.
    Pardo Aranda, N.
    Juan-Vidal, O.
    Cheng, Y.
    Zhang, H.
    Shi, M.
    Luft, A.
    Wolf, J.
    Antonia, S.
    Nakagawa, K.
    Fairchild, J.
    Baudelet, C.
    Pandya, D.
    Doshi, P.
    Chang, H.
    Reck, M.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 631 - 641
  • [20] Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer
    Hirose, Takashi
    Nakashima, Masanao
    Shirai, Takao
    Kusumoto, Sojiro
    Sugiyama, Tomohide
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Ohnishi, Tsukasa
    Ohmori, Tohru
    Adachi, Mitsuru
    LUNG CANCER, 2011, 73 (03) : 345 - 350
12345